Trials / Recruiting
RecruitingNCT06150560
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
A Phase III, Randomized, Double-Blind, Placebo Controlled Clinical Trial Evaluating the Benefits and Mechanism Of Action Of Angiotensin-II Receptor Blocker On Cardiovascular Remodeling In Patients With Repaired Coarctation Of Aorta
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Losartan | 50mg administered orally once daily for 52 weeks. |
| DRUG | Amlodipine | 5mg Amlodipine administered orally once daily for 52 weeks. |
| DRUG | Placebo | Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks. |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2023-11-29
- Last updated
- 2025-08-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06150560. Inclusion in this directory is not an endorsement.